Kite Pharma (KITE) : Zacks Investment Research ranks Kite Pharma (KITE) as 3, which is a Hold recommendation. 7 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 1.33, which indicates as a Strong Buy.
Kite Pharma (KITE) : The most positive equity analysts on Kite Pharma (KITE) expects the shares to touch $87, whereas, the least positive believes that the stock will trade at $58 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $70.75 with an expected fluctuation of $9.91 from the mean.
For the current week, the company shares have a recommendation consensus of Buy.
Kite Pharma (NASDAQ:KITE): The stock opened at $48.04 on Tuesday but the bulls could not build on the opening and the stock topped out at $48.38 for the day. The stock traded down to $46.89 during the day, due to lack of any buying support eventually closed down at $46.96 with a loss of -1.51% for the day. The stock had closed at $47.68 on the previous day. The total traded volume was 1,416,380 shares.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Companys lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.